| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $861K | +3.0% | -12.8% |
| Cost of Revenue | $49K | +6.5% | -27.9% |
| R&D Expense | $14.0M | +1.3% | +21.0% |
| SG&A Expense | $7.1M | +13.3% | +25.3% |
| Operating Income | -$20.3M | -5.1% | -24.3% |
| Net Income | -$20.8M | -7.6% | -35.0% |
| EPS (Basic) | -$0.40 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $42.0M | +124.1% | +64.1% |
| Short-term Investments | $53.8M | +254.6% | +30.2% |
| Accounts Receivable | $52K | -37.3% | -54.8% |
| Inventory | $365K | +97.3% | +56.0% |
| Current Assets | $97.8M | +172.5% | +42.6% |
| Total Assets |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$46.7M | — | — |
| Capital Expenditures | $456K | — | — |
| Investing Cash Flow | -$9.2M | — | — |
| Financing Cash Flow | $75.7M | — | — |
| Free Cash Flow | -$47.1M | — | — |
| +20.0% |
| +2.4% |
| EPS (Diluted) | -$0.40 | +20.0% | +2.4% |
| $104.8M |
| +144.7% |
| +39.2% |
| Current Liabilities | $20.7M | +21.1% | +27.4% |
| Long-term Debt | $15.0M | +0.0% | — |
| Total Liabilities | $61.1M | +43.6% | +109.9% |
| Stockholders' Equity | $43.7M | — | -5.4% |